After 24 hours, this combination therapy synergized to increase the number of apoptotic RMS cells, suggesting that the dual-drug therapy with low doses of RCM1 and VCR induces tumor cell death with higher efficiency than single agents alone (Figure 1E). This evidence concerns the gene TNNI3 and neoplasm.